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Abstract
Background: Molecular diagnosis of glycogen storage diseases (GSDs) is important to enable accurate diagnoses
and make appropriate therapeutic plans. The aim of this study was to evaluate the PHKA2 mutation spectrum in
Korean patients with GSD type IX.
Methods: Thirteen Korean patients were tested for PHKA2 mutations using direct sequencing and a multiplex
polymerase chain reaction method. A comprehensive review of the literature on previously reported PHKA2
mutations in other ethnic populations was conducted for comparison.
Results: Among 13 patients tested, six unrelated male patients with GSD IX aged 2 to 6 years at the first diagnostic
work-up for hepatomegaly with elevated aspartate transaminase (AST) and alanine transaminase (ALT) were found
to have PHKA2 mutations. These patients had different PHKA2 mutations: five were known mutations (c.537 + 5G > A,
c.884G > A [p.Arg295His], c.3210_3212delGAG [p.Arg1072del], exon 8 deletion, and exons 27–33 deletion) and one was
a novel mutation (exons 18–33 deletion). Notably, the most common type of mutation was gross deletion, in contrast
to other ethnic populations in which the most common mutation type was sequence variant.
Conclusions: This study expands our knowledge of the PHKA2 mutation spectrum of GSD IX. Considering the PHKA2
mutation spectrum in Korean patients with GSD IX, molecular diagnostic methods for deletions should be conducted
in conjunction with direct sequence analysis to enable accurate molecular diagnosis of this disease in the Korean
population.
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Background
Glycogen storage disease type IX (GSD IX) is caused by
a general deficiency in phosphorylase kinase (PhK),
which plays a major role in regulating the breakdown of
glycogen. The PhK enzyme is composed of four copies
each of four subunits (α, β, γ, and δ [also known as cal-
modulin]), which are encoded by PHKA1 and PHKA2
for the α subunits, PHKB for the β subunits, PHKG1
and PHKG2 for the γ subunits, and CALM1, CALM2,
and CALM3 for the δ subunits [1]. There are autosomal
recessive forms of GSD IX (caused by mutations in PHKB,
PHKG1, PHKG2, CALM1, CALM2, and CALM3), a X-
linked liver form (caused by mutations in PHKA2), and a
X-linked muscle form (caused by mutations in PHKA1).
Specifically, the α subunits, which are encoded by the
PHKA2 gene in liver and by PHKA1 in muscle, regulate
the activity of the catalytic γ subunits, which carry out the
function of PhK. Mutations in PHKA2 are the most com-
mon cause of PhK deficiency [2].
The clinical manifestation of GSD IX stemming from
PHKA2 mutation is characterized by childhood onset of
hepatomegaly, growth retardation, fasting ketosis, and
fasting hypoglycemia [3]. Symptoms and biochemical ab-
normalities in GSD IX patients have been reported to
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improve with age [4]. However, several GSD IX patients
possessing PKHA2 mutations have been reported to pro-
gress to liver cirrhosis, or even present with cirrhosis at
the time of diagnosis [4, 5].
GSD is a clinically and genetically heterogeneous group
of diseases. Different types of GSD can sometimes be clin-
ically indistinguishable; for example, both GSD VI and
GSD IX often manifest with hepatomegaly with short
stature [3]. Molecular diagnosis of GSD provides the ad-
vantage of avoiding invasive liver biopsy [6] and is an im-
portant starting point for appropriate therapeutic and
monitoring plans [7]. Furthermore, molecular diagnosis al-
lows determination of the inheritance pattern (autosomal
recessive vs. X-linked) and DNA testing for other family
members when the mutation in the proband is known.
The PHKA2 gene is located at chromosomal locus
Xp22.2-p22.1 and consists of 33 exons spanning more
than 65 kb and encoding a protein of 1,235 amino acids
[8]. Sequence analysis of this X-linked gene can detect
small intragenic deletions/insertions and missense, non-
sense, and splice site mutations in males and females,
and lack of amplification by PCR prior to sequence ana-
lysis can suggest a putative exonic or whole-gene deletion
on the X chromosome in affected males [9]. Understand-
ing the mutation spectrum of causative genes in different
ethnic groups could provide background knowledge to de-
velop a tailored diagnostic approach for different patient
populations [7].
To date, data on PHKA2 mutations in Korean patients
with GSD IX are available for only two cases. Thus, the
aim of this study was to evaluate the mutation spectrum
in Korean patients with GSD IX and compare it with




From May 2010 to April 2015, blood samples from 13
unrelated Korean children were collected for PHKA2
mutation analysis at Samsung Medical Center. The study
population included two female patients with hepato-
megaly and elevated aspartate transaminase (AST) and/
or alanine transaminase (ALT) who were undergoing
PHKA2 sequencing because no pathogenic mutations in
G6PC (for GSD Ia), which is known to a common causa-
tive gene of glycogen storage disease in the Korean
population, were identified during diagnostic work up
for their hepatomegaly [10, 11]. Blood samples from
healthy individuals, who visited the health promotion
center at Samsung Medical Center for regular health
checkups without any clinical symptoms or signs of ill-
nesses, and who volunteered for blood sampling, were
also collected as negative controls for identified muta-
tions. This study was conducted according to the
guidelines laid down in the Declaration of Helsinki and
all procedures involving human subjects were approved
by the Institutional Review Board of Samsung Medical
Center. Written informed consent was obtained from all
subjects and/or their parents.
PhK enzyme activity
PhK enzyme activity in erythrocytes was measured ac-
cording to a previously described method [12, 13]. The
results of enzyme activity were expressed as μmol/mi-
nute (min)/g hemoglobin (gHb). The reference range of
phosphorylase b kinase enzyme activity in the laboratory
was 100.0 to 250.0 μmol/hr/g Hb [12], which was vali-
dated using erythrocytes from healthy subjects. Each test
was performed simultaneously in duplicate and with
erythrocytes obtained from two different healthy sub-
jects. Test results were accepted when the results of
healthy control samples were within the reference range
and the coefficient of variation of duplicated results was
less than 10 %.
Quantitation of liver glycogen
Liver glycogen was measured according to a previously
described method [14]. Fresh liver samples, 45 μL in vol-
ume, were homogenized, heated at 95 °C for 5 min, and
mixed with 45 μL of 0.1 M sodium acetate buffer
(pH 4.8), and 9 μL of amyloglucosidase. Each homogen-
ate was sonicated and incubated at 37 °C for 30 min and
then at 95 °C for 5 min. Glycogen levels per gram of wet
liver were calculated as glucose released by amylogluco-
sidase; i.e., glucose level after incubation with amyloglu-
cosidase minus that without enzyme. The results were
expressed as % glycogen/g wet liver weight. The refer-
ence range of liver glycogen in the laboratory was 1.0 to
6.0 % per gram of wet liver weight.
PHKA2 mutation analysis
Human genomic DNA was prepared from frozen white
blood cells using a Wizard genomic DNA purification
kit (Promega, Madison, WI, USA) according to the man-
ufacturer’s recommendations. All 33 exons and the
flanking regions of the PHKA2 gene were amplified by
polymerase chain reaction (PCR) using primers designed
by the authors (Table 1) with a thermal cycler (Model
970; Applied Biosystems, Foster City, CA, USA). Direct
sequencing of the DNA was performed using the ABI
Prism 3100 Genetic Analyzer (Applied Biosystems) with
the BigDye Terminator Cycle Sequencing-Ready Reac-
tion Kit (Applied Biosystems). Nucleotides are numbered
from the first adenine of the ATG translation initiation
codon in the PHKA2 cDNA Reference Sequence
NM_000292.2.
To detect single or multiple exon deletions, a multiplex
PCR method was performed using primers designed by the
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authors (Table 1). All tests were performed concurrently
on negative control samples from healthy individuals.
Additionally, a comprehensive review of the literature
on previously reported PHKA2 mutations in Asian pop-
ulations was conducted. The Leiden Open Variation
Database (LOVD, http://www.LOVD.nl/PHKA2) and
Human Gene Mutation Database (HGMD, h https://por-
tal.biobase-international.com/cgibin/portal/login.cgi
were checked for previously reported sequence variants.
Variants identified in this study were checked through
public databases. Common and rare variants present in
the PHKA2 gene in Korean population could be ob-
tained from the Korean Reference Genome Database
(http://152.99.75.168/KRGDB/) and compared with
other ethnic populations through the Exome Aggrega-
tion Consortium (ExAC), which aggregates over 60,000
Table 1 Primers used for PCR, sequencing, and multiplex PCR for PHKA2 mutation analysis
Exon Forward primer sequence Reverse primer sequence Product size (bp)
PHKA2
1 CCATCCCAAGAACCGACTAA GCAACAGTTAGGTCCCCTGA 395
2 AGGTCCCGGTCCTCATCTAC GAGAGGCCTACACCCAAACA 367
3 AGCCACAGTGATCAGGAGGT AATGACATGGAATGCCCACT 174
4 GCTGGGACATTTTAGGCAAG CACATGGCCTGACACACTG 467
5 CCTTCCCTCTTTTCGGAGAT GCAGTTTGTGTGTGGAGGTG 419
6 GGCTGCAGGAACATAAAGGA CCAGGACGGAGCACTCTTAC 401
7 TTGCTTAATGAAAAAGGAACACC CTAGCTTGTGAGGCCAGAGG 349
8 TGACTTCTCGCCTGAGGAAT ACCTCATGGGGAACTGAGG 427
9 TATCTGCCTTGGTGGCTTTT CCAGCTCACCGTCCCTACTA 434
10 TCAGTCAAGCATGGGAAACC CTCTGCCCAAATTGCAGAAT 414
11 CCGATCGTGTTTAGCTCCTC TCCCAAAGTGCTGGGATTAC 475
12 ATTGGCCTGGAGGATGAGTA TGGACACACAAGGCTGAGAG 399
13 TGAATATGTTGAGCCCCAAA CCCAGTTGCAATCAAGGTT 428
14 ATGTCACCAGGCAGAAGAGG CCGCCTGCTTTAGTTTTTGT 353
15 GAAGAACCAAGCCCCAAAAT ACGCCTGTCTCAAAAAGCAT 421
16 ACTGGGTGGATTGAAACGAG AGAAGCCCCTTCAGTGCTTA 389
17 CGGGAATCTTCTATGCCAGA TGGTTCACCTCCCTATGTCC 444
18 CCACATGGTTGTGCAAAAGT CGGTTTTTAAACGGGCATT 441
19 GCTTGCTACCCATGGTCACT GGGGCATTTTGTTGTCTTCT 364
20 GAGGCAAAGGTTGCAGTGAG TGCAAGTCAGATTCCAGACAA 412
21 GAAAACTGGAGCACAGCACA CCATGTCAGGATGCAATGAG 434
22 ACCACGTCCTGATGTTAGGC ATGGGGCTCCTTCACAAGTA 449
23 TCCCTGTCTGGGTTGCTTAG AGACGCATCCATGTGACAGA 382
24 TCTGTCACATGGATGCGTCT TCTCCTGAGGCAGACACACA 303
25 ACAGCCTTCCTCAGAGTGGA GGATGCTGGGTTCGAGATAA 321
26 TTTCAGCCCCAAAGCAATAG ACACTGCGAGCAAGTCTCAA 435
27 CAGAGAAGGCCCTCATTGTC GGACAGGGGTGTGTTCAGAT 376
28 CCATGAGAAATGCACTCGAA ATAGAGCCGCCCTCTACACA 337
29 CTCTGCTGCTGCTTTCTGTG GACGGAGAACAAAGCTCAGG 365
30 GTGGTGTTCTGGCATTTGTG ATCCTCAGGGCTGTGTGTTT 383
31 TGTTCCATCGAAAACACAGC TGATGCCAATAAATGCTGGA 436
32 GCTACGGTCACCCTTGGTTA TTTTTCCCCATCATCTGTGA 410
33 CTCAGAAGGCCAAGGCTCTA CTGATGGGACATGCTTTCCT 415
MECP2a
4 CGCTCTGCCCTATCTCTGAC TCCCCTCGGTGTTTGTACTT 1061
aUsed as amplification control of MECP2 gene exon 4 located in Xq28 for multiplex PCR
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human exomes. The 1000 Genomes Project database
(http://browser.1000genomes.org), the National Heart,
Lung, and Blood Institute (NHLBI) Exome Sequencing
Project (ESP) database (http://evs.gs.washington.edu/
EVS), and the NCBI database of Single Nucleotide Poly-
morphisms (dbSNPs) were also checked for previously
reported sequence variants.
The pathogenicity of missense variants was evaluated by
in silico analyses using Sorting Intolerant from Tolerant
(SIFT) (http://sift.jcvi.org/), and Polymorphism Phenotyp-
ing v.2 (PolyPhen-2) (http://genetics.bwh.harvard.edu/
pph2/) prediction programs. Human Splice Finder soft-
ware (http://www.umd.be/HSF3/) was used to predict
splicing signals [15].
Results
During the study period, six patients were identified as
having PHKA2 mutations. All six patients were male.
Clinical and biological information at the time of diag-
nosis are detailed in Tables 2 and 3. Median age at first
diagnostic work-up was 3 years (range 2–4 years). All
patients presented with hepatomegaly and elevated AST
and/or ALT as the first clinical features. Short stature,
defined as height below the 3rd percentile for age by
Korean Children and Adolescents Growth Standard [16],
was observed in 33.3 % (2/6 patients, case 3 and 4) of
GSD IX patients. The height of case 2, who had a mis-
sense mutation of c.884G > A (p.Arg295His), was within
the 25th to 50th percentile. Among these six patients,
only two had been tested for PhK enzyme activity in
their erythrocytes, and both showed decreased PhK ac-
tivity. Liver biopsies had been performed for five pa-
tients. Among them, the results of four (patients 3, 4, 5,
and 6) were compatible with glycogen storage disease:
Periodic acid–Schiff (PAS) staining was positive and PAS
diastase stain was negative. One patient who was
referred from an outside hospital was reported to be
PAS+ in liver biopsy, but limited information was avail-
able because the liver biopsy had been performed at the
outside hospital. All patients initiated uncooked corn-
starch therapy after diagnosis of GSD. None of the pa-
tients experienced symptomatic fasting hypoglycemia at
the time of diagnosis or during the follow-up period. Glu-
cose monitoring, in which blood glucose was measured
upon waking in the morning in a fasting state, identified
one episode of asymptomatic fasting hypoglycemia
(<70 mg/dL) [17] in each of case 2 and case 6.
Each of the six patients had a different PHKA2 muta-
tion. Among the six mutations, five were known muta-
tions—c.537 + 5G > A [6], c.884G > A (p.Arg295His) [8],
c.3210_3212delGAG (p.Arg1072del) [18, 19], exon 8 de-
letion [13], and exons 27–33 deletion (Fig. 1) [6]—and
one was a novel mutation (exons 18–33 deletion). None
of these mutations was observed in control population
databases. The novel deletion mutation identified in case
5 was the largest deletion mutation (16 exons) ever re-
ported among GSD IX patients, except for patients re-
ported in the literature with full PHKA2 deletion who
had no paternal X-chromosome (LOVD). However, there
was a lack of formal information on whether these
patients had Turner syndrome, and therefore only one
copy of PHKA2. Caution is required when using infor-
mation from public databases and it is necessary to clar-
ify the status of these patients.
Our review of the literature on PHKA2 mutations in
Asian populations with GSD IX is summarized in
Table 4. Among 18 different PHKA2 mutations reported
in Asian populations, nine (50 %) were splicing or dele-
tion mutations. The overall PHKA2 mutation spectrum
derived from a comprehensive literature review is sum-
marized in Fig. 2. The most common PHKA2 mutation
type among other ethnic groups and Asian populations
Table 2 Summary of the clinical features of six GSD IX patients with PHKA2 mutation
Patient
no.


















1 M 2 Yes No No No No Yes Yes No Yes 13
2 M 6 Yes No No Yesg No Yes No No No 26
3 M 4 Yes Yes Yes No No Yes No No No 178
4h M 2 Yes Yes Yes No No Yes Yes No Yesi 48
5 M 2 Yes No No No No Yes Yes No Yes 33
6 M 4 Yes No No Yesg No Yes No Not done Yes 4
aAge at first diagnostic workup
bShort stature was defined as height below the 3rd percentile for age by Korean Children and Adolescents Growth Standard
cUric acid level > 7.2 mg/dL for at least one measurement during follow-up period
dLactic acid level > 2.2 mmol/L for at least one measurement during follow-up period
eTotal cholesterol > 240 mg/dL and/or triglyceride >200 mg/dL for at least one measurement during follow-up period
fSerum creatine kinase >204 IU/L for at least one measurement during follow-up period
gGlucose monitoring in which blood glucose was measured upon waking in the morning in a fasting state identified one episode of asymptomatic fasting
hypoglycemia (<70 mg/dL) during the follow-up period. The patient did not experience symptomatic hypoglycemia
hX-linked inheritance was identified by maternal PHKA2 mutation analysis
iMild improvement from two fingerbreadths to one fingerbreadth during follow-up period
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other than Koreans was sequence variants, such as mis-
sense, nonsense, or frameshift mutations.
Discussion
In this study we examined the PHKA2 mutation
spectrum in Korean patients with GSD IX. GSD IX is as-
sociated with a deficiency in liver PhK (caused by muta-
tions in PHKA2, PHKB and PHKG2) or the muscle form
of PhK (caused by mutations in PHKA1). Mutations in
PHKA2 have been reported to be the most common
cause of GSD IX (responsible for approximately 75 % of
cases) [20, 21]. The second most common cause of liver
PhK deficiency is mutations in PHKG2 (autosomal
recessive), followed by PHKB (also autosomal recessive)
[3]. X-linked liver glycogenosis (XLG) caused by PHKA2
mutations can be divided into two subtypes: XLG I with
no detectable activity of phK in liver and peripheral
blood cells, and XLG II with normal activity in periph-
eral blood cells and deficiency in the liver [8]. Although
several female GSD IX patients with PHKA2 mutations
have been reported in other populations, including
Western and other Asian populations [18, 22–24], only
male patients were identified among our Korean patient
population. The PHKA2 mutation spectrum is known to
be distributed across the entirety of PHKA2 exons, with
the exception of exon 13. Except for amino acids 420,
Table 3 Mutations found in six Korean patients with GSD type IX
Case no. Sex Agea (yrs) PhK in erythrocytesb
(μmol/min/gHb)
Liver glycogenc Liver biopsy Identified mutation Mutation type Ref.
1 M 2 Not done Not done Not done c.537 + 5G > A Splicing [6]
2 M 6 Not done Not done PAS(+)d c.884G > A (p.Arg295His) Missense [8]






Small deletion [18, 19]
4 M 2 6.57 Not done c/w GSD Exon 8 deletion Gross deletion [13]
5 M 2 Activity below
detection level
25.1 % c/w GSD, PAS(+),
D-PAS(−)
Exons 18–33 deletion Gross deletion This study
6 M 4 Not done Not done c/w GSD, PAS(+),
D-PAS(−)
Exons 27–33 deletion Gross deletion [6]
c/w compatible with, D-PAS Periodic acid–Schiff diastase stain, f/u follow-up, PAS Periodic acid–Schiff stain, PhK Phosphorylase b kinase, Ref references
aAge at first diagnostic workup due to clinical presentation (all patients presented with hepatomegaly with elevated aspartate aminotransferase and
alanine aminotransferase)
bReference range of the laboratory was 100.0–250.0 μmol/min/gHb
cReference range of the laboratory was 1–6 %/g wet liver weight
dOnly limited information available on results of liver biopsy performed at outside hospital
Fig. 1 Example of a large exonic deletion identified in patient 6. a Lack of amplification of PCR products from exon 27 to exon 30 of the PHKA2
gene in patient 6 compared with normal control. b Multiplex PCR results using control primers for amplification of MECP2 gene exon 4 (1,061 bp)
located in Xq28 and test primers for amplification of exon 26 (435 bp), exon 27 (376 bp), and exon 33 (415 bp)
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423, and 432–434, the protein sequence of PHKA2 is
strictly conserved among various mammals and zebra-
fish (Fig. 3). Exon 13, which corresponds to amino acids
416 to 442, is in a six-hairpin glycosidase domain (amino
acids 9 – 453) that contains pathogenic mutations in-
cluding several missense mutations [2]. Although several
missense variant alleles have been identified in exon 13
(ExAC), hemizygosity and lack of clinical information
make interpretation of their clinical significance difficult.
Further studies are needed to clarify the clinical signifi-
cance of mutations in exon 13.
No recurrent mutations were observed among Korean
GSD IX patients, although a missense PHKA2 mutation
of p.Pro1205Leu suggestive of a founder mutation has
been reported among Dutch patients [22]. This muta-
tion has also been reported in Japanese and Chinese
patients, but has not been observed in the Korean
population [22, 24, 25].
In this study, we identified one novel and five known
PHKA2 mutations. The missense mutation of c.884G >A
(p.Arg295His) has been reported in a patient with un-
usually severe clinical manifestation with marked ketosis
and hyperlipidemia [8, 26] In our study, patient 2 carrying
the same mutation showed a relatively mild clinical mani-
festation, with asymptomatic hepatomegaly and asymp-
tomatic hypoglycemia and height and weight within the
25th to 50th percentiles, although he had experienced
hyperlactic acidemia. This mutation has been reported
previously in a patient with XLG I who had a pronounced
PhK deficiency in both liver and erythrocytes (PhK activity
was 10.0 % of the control mean in both liver and erythro-
cytes) and in a patient with XLG II who had normal
erythrocyte PhK activity (83.0 % of the control mean),
therefore the significance of this mutation for biochemical
function in specific tissues and clinical severity remains
speculative [8]. This mutation was predicted to affect pro-
tein function by in silico analyses (SIFT and PolyPhen-2)
and was predicted to alter splicing through activation of
an exonic cryptic donor site by both Human Splice Finder
software and by a machine-learning technique that scores
Table 4 Reported PHKA2 mutations in Asian patients with glycogen storage disease (GSD) type IX
Ethnicity Exon number Nucleotide change Amino acid change Mutation type Reference
Point mutation
Chinese 2 c.136delG p.Asp46Ilefs*37 Frameshift [31]
Japanese 4 c.346 T > G p.Tyr116Asp Missense [32]
Japanese 6 c.578G > T p.Gly193Val Missense [32]
Japanese 9 c.883C > T p.Arg295Cys Missense [25]
Korean 9 c.884G > Aa p.Arg295His Missense [8], This study
Japanese 15 c.1489C > T p.Arg497* Nonsense [25]
Japanese 16 c.1697A > T p.Ile566Asn Missense [33]
Japanese 32 c.3505C > T p.Gln1169* Nonsense [25]
Japanese, Chineseb 33 c.3614C > T p.Pro1205Leu Missense [22, 24, 32, 34]
Splicing mutation
Japanese 2 c.79-1G > T Exon 2 skipping Splicing [25]
Korean IVS5 c.537 + 5G > A ?c Splicing [6], This study
Japanese 25 c.2675A > G Exon 25 skipping Splicing [32]
Chinese 30 c.3112-1G > A Exon 30 skipping Splicing [31]
Deletion mutation
Korean 30 c.3210_3212delGAG p.Arg1072del Small deletion [18, 19], This study
Korean 8 Exon 8 deletion Gross deletion [13], This study
Korean 18–33 Exon 18–33 deletions Gross deletion This study
Japanese 20–26 Exon 20–26 deletions Gross deletion [29]
Korean 27–33 Exon 27–33 deletions Gross deletion [6], This study
aThis mutation has been reported previously in two patients with GSD IX and is predicted to affect protein function by in silico analyses (SIFT and PolyPhen-2) and
to affect splicing, potentially through activation of an exonic cryptic donor site, by both Human Splice Finder software and by a machine-learning technique that
scores how strongly genetic variants affect RNA splicing [27]
bThis mutation has been reported as a founder mutation in the Dutch population
cAlthough in vitro analysis for the splicing effect of c.537 + 5G > A was not performed, in vivo results confirming phosphorylase b kinase deficiency have been
reported to constitute a pathogenic mutation in a patient with GSD IX in previous literature. This mutation was predicted to affect splicing, potentially through
alteration of the wild-type donor site
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how strongly genetic variants affect RNA splicing [27].
The c.537 + 5G >A mutation has been reported in a male
GSD IX patient of European ancestry who presented with
hepatomegaly and growth delay that presented from
9 months of age [6]. This mutation was predicted to affect
splicing through alteration of the wild-type donor site. Al-
though in vitro analysis of the splicing effect of c.537 +
5G >A was not performed, in vivo results confirmed
phosphorylase b kinase deficiency in the patient’s lympho-
cytes (32 U/g, normal range 100–240 U/g) and erythro-
cytes (0.7 U/g Hb, normal range 4–10 U/g Hb) [6].
Clinical manifestations of the patient carrying this
mutation were reported to include growth delay, mild
fasting hypoglycemia, post-prandial lactatemia, and
elevated serum triglycerides, with age at onset of
9 months [6]. In our study, patient 1 carrying the
same mutation had post-prandial lactatemia and ele-
vated serum triglycerides in common, but no fasting
hypoglycemia or growth delay. A small deletion muta-
tion of c.3210_3212delGAG (p.Arg1072del) has been
reported in a Finnish male GSD IX patient with hepato-
megaly without short stature or hyperlactic acidemia [18]
whose age at onset was 16 months. That patient was diag-
nosed with GSD IX by molecular diagnosis, but a PhK en-
zyme activity test was not performed [18]. In this study,
the patient with the same mutation was of short stature
and his liver glycogen concentrations increased over time
(8.8 %/g wet liver weight at initial diagnosis and 22.5 %/g
Fig. 2 Summary of reported PHKA2 mutation spectrum: a PHKA2 mutation types among all reported mutations in all ethnic populations; b PHKA2
mutation types identified in Asian GSD IX patients (other than Korean); c PHKA2 mutation types identified in Korean GSD IX patients; d Number of
reported PHKA2 mutations in each exon (excluding gross deletions spanning more than one exon). The x-axis is the number of each coding exon
and the y-axis is the number of identified mutations. *Gross deletion spanning more than one exon designated by additional asterisk and lines
Fig. 3 Evolutionary conservation of the amino acid residues for exon 13 on PHKA2 gene. Except for several amino acid sites, such as amino acid
420, 423, and 432–434, other amino acid residues are strictly conserved in various mammals and zebrafish
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wet liver weight at 2.5 year follow-up; reference range
1–6 %/g wet liver weight). His age of onset was 4 years
and he experienced hyperlactic academia, which was dif-
ferent from the Finnish male. A gross deletion mutation
of exons 27–33 has been reported in a male GSD IX pa-
tient of European ancestry with PhK deficiency diagnosed
by markedly decreased phosphorylase activities in his
lymphocytes and erythrocytes, whose age at onset was
8 months [6]. Because PhK (defective PhK activities cause
GSD IX) activates glycogen phosphorylase b (defective
phosphorylase activities cause GSD VI) by phosphoryl-
ation, patients with GSD IX can have decreased phosphor-
ylase activities [6]. Molecular studies and analysis of PhK
are needed to make the correct diagnosis and avoid
misdiagnosis of GSD VI [28]. The male patient in the pre-
vious literature was reported to have post-prandial lactate-
mia with elevated serum triglycerides [6]. In this study,
patient 6 carrying the same large deletion had asymptom-
atic fasting hypoglycemia and post-prandial lactatemia but
no elevated serum triglycerides. His age at first diagnostic
workup was 4 years.
Of note, most mutations in Korean GSD IX patients
were deletion or splicing mutations, except for one
known missense mutation of c.884G > A (p.Arg295His)
[8]. Fifty percent of Korean GSD IX patients had gross
deletion mutations, and 83.3 % had splicing or deletion
mutations that were different from those reported in
other ethnic populations. These results suggest that la-
boratory tests for large deletions in PHKA2 should be
included in the variety of methods that may be used
such as quantitative PCR, long-range PCR, multiplex
ligation-dependent probe amplification, and that
chromosomal microarrays including this gene/chromo-
some segment should be used as the first approach for
Korean patients suspected to have GSD IX [9]. In this
study, the presence of deletions in male GSD IX patients
was initially implied by the lack of amplification of exons
by PCR and additional multiplex PCR was then was
employed to better define the deletion. Although only
male patients had PHKA2 mutations in this study, multi-
plex PCR would be necessary to detect deletions in fe-
males with suspected GSD IX [9]. Methods to detect
deletions would be important for patients of all ethnici-
ties [6, 9, 29].
Historically, diagnosis of GSD was based on enzymatic
defects of each type of GSD or on liver histopathology
compatible with GSD [6]. Recent molecular diagnostic
approaches based on mutation analysis for disease-
causing genes associated with each type of GSD provide
the advantages of avoiding invasive liver biopsy and
allowing differentiation between several types of GSD
with similar clinical findings [6].
Because of its variable clinical manifestations with
mild symptoms, underestimation of GSD IX is possible.
For example, short stature was observed in 33.3 % of pa-
tients in this study, which was comparable to previous
studies in European and Argentinian populations [18]
but different from a Canadian study that reported no pa-
tients with short stature [3]. Furthermore, the effect of
PHKA2 mutations on tissues other than liver should be
clarified through future studies. A recent study reported
that genetic diagnosis for X-linked mental retardation
revealed several PHKA2 variants [30]. Although the
natural history of GSD IX in Canadian patients has been
reported, there are no reliable data on long-term out-
comes for Korean GSD IX patients [3]. The study on 11
Canadian GSD IX patient with PHKA2 mutations with a
follow-up period ranging from 1 to 16 years reported
improved, normalized, or stable liver enzymes in all pa-
tients, and development of likely liver adenoma in one
patient at the 5-year follow-up [3]. Detailed long-term
natural history studies of Korean patients with GSD IX
caused by PHKA2 mutation will be helpful to under-
stand whether these patients are at increased risk of de-
veloping additional complications such as liver cirrhosis
or hepatocellular carcinoma, or other conditions such as
reproductive or mental disorders, later in life.
PhK deficiency is very complex and many genes play a
key role in the GSD IX phenotype; the spectrum in-
cludes autosomal recessive forms of GSD IX (caused by
mutations in PHKB, PHKG1, PHKG2, CALM1, CALM2,
and CALM3) as well as the X-linked liver form (caused
by mutations in PHKA2) and X-linked muscle form
(caused by mutations in PHKA1). Only PHKA2 muta-
tions were studied in this study. Future studies involving
comprehensive mutational analyses of multiple causative
genes in the Korean population are needed.
Conclusions
In this study we summarized the PHKA2 mutation
spectrum in Korean GSD IX patients and found that the
most common mutation type was gross deletion. The
present study expands our knowledge of the mutational
spectrum in Korean GSD IX patients, which differs from
that in other ethnic populations. Considering the
PHKA2 mutation spectrum in Korean patients with
GSD IX, molecular diagnostic methods for deletions
should be combined with direct sequence analysis to
provide accurate molecular diagnosis of this disease.
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